OxfordOxford Mon - Fri 09:00-17:00 +44(0)1865-600222
LibPubMedia1@gmail.com
OxfordOxford Mon - Fri 09:00-17:00 +44(0)1865-600222
LibPubMedia1@gmail.com
J Venom Res
Open-access
Aptamers
Open-access
Aptamers 2019
03-04 April 2019, Oxford
Submit a manuscript

Blog Full Left Sidebar

Caption aligned here
A wonderful serenity has taken possession of my entire soul, like these sweet mornings of spring which I enjoy with my whole heart. I am alone, and feel the charm of existence in this spot, which was created for the bliss of souls like mine. I am so happy, my dear friend, so absorbed in the...
Read More
TAGCyx Biotechnologies Inc. is a drug discovery and development company based in Japan, spun out of Riken Research Institute. We utilizes its proprietary, artificial nucleotide base pair technology invented by Dr. Ichiro Hirao to generate unique DNA aptamer, Xenoligo®, for therapeutic purposes.  Amongst various type of aptamers, the advantage of Xenoligo® are: 1) comprised of DNA, 2)...
Read More
ATDBio was established to provide high quality oligonucleotides to scientists around the world. ATDBio oligonucleotides are used successfully in academic and commercial research in the fields of genetics, genomics, molecular biology, biochemistry, biotechnology and nanotechnology. We supply a wide range of custom-made unmodified and chemically modified oligonucleotides for small and large scale applications. ATDBio specialises in highly modified...
Read More
RIBOMIC Inc is a biopharmaceutical venture company based in Tokyo. The company is developing molecular targeted pharmaceutical drugs using RNA aptamers with its unique and advanced platform technologies called the RiboART System. RIBOMIC has been promoting the pharmaceutical discovery program in collaboration with Otsuka Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., The University of Tokyo, and some other...
Read More
Aptamer Solutions Ltd: Continued success and growth has enabled Aptamer Group to restructure its Scientific Operations team. Increasing interest in the development of aptamers against small molecule targets has led to the formation of a dedicated scientific team. This is in addition to the existing team focused on aptamer generation against larger targets (proteins, viruses, cells...
Read More
PROTOCOL/METHOD ISSN: 2514-3247 Aptamers (2018), Vol 2, in press Published online: 12 June 2018 Full Text Access  Sladjana Slavkovic and Philip E. Johnson* Department of Chemistry and Centre for Research on Biomolecular Interactions, York University, Toronto, Ontario, Canada, M2R 1A1 *Correspondence to: Philip Johnson, Email: pjohnson@yorku.ca, Tel: 1 416 736 2100 x33119 Received: 31 January 2018 |...
Read More
1 2 3 36

Text Widget

Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.

Recent News

TAGCyx (Japan) – Our Bronze Sponsor
February 1, 2019
ATDBio (UK) – Our Bronze Sponsor
February 1, 2019
Ribomic Inc (Japan) – Our Gold Sponsor
December 8, 2018

Recent Cases